News & Updates

Show Multimedia Only

TNFi treatment in rheumatic disease not a risk for COVID-19 hospitalization

23 Jun 2021 by

Analysis of the German COVID-19 registry suggests that patients with rheumatic or musculoskeletal diseases (RMDs) who are treated with tumour necrosis factor (TNF) inhibitors appear to be at lower risk of severe outcomes of COVID-19 compared with those treated with other (non-TNF inhibitor) immunomodulatory treatments (OIDs).

TNFi treatment in rheumatic disease not a risk for COVID-19 hospitalization

23 Jun 2021

Dupilumab may reduce exacerbations in paediatric uncontrolled asthma

22 Jun 2021 by

Children with uncontrolled moderate-to-severe asthma may benefit from treatment with dupilumab which reduced exacerbations and improved lung function, according to results of the phase III VOYAGE study presented at ATS 2021.

Dupilumab may reduce exacerbations in paediatric uncontrolled asthma

22 Jun 2021

News & Updates

Showing Respirology articles

Showing

Specialty:

TNFi treatment in rheumatic disease not a risk for COVID-19 hospitalization

TNFi treatment in rheumatic disease not a risk for COVID-19 hospitalization

Dupilumab may reduce exacerbations in paediatric uncontrolled asthma

Dupilumab may reduce exacerbations in paediatric uncontrolled asthma